Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study - 10/03/21
Funding sources: The study was funded by Ortho Dermatologics (Bridgewater, NJ). |
|
Disclosure: Dr Eichenfield has served as an investigator and/or consultant for AbbVie, Incyte, LEO Pharma, Lilly, Novartis, Pfizer, Regeneron, Ortho Dermatologics, and Sanofi. Dr Elewski has provided clinical research support (research funding to the university) for AbbVie, Anaptys-Bio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Incyte, LEO Pharma, Lilly, Merck, Menlo, Novartis, Pfizer, Regeneron, Sun Pharma, Ortho Dermatologics, and Vanda and has served as a consultant (and received honoraria) for Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, LEO Pharma, Lilly, Menlo, Novartis, Pfizer, Sun Pharma, Ortho Dermatologics, and Verrica. Dr Sugarman is a consultant for Ortho Dermatologics, Bausch Health, Regeneron, Sanofi, Verrica, and Pfizer. Dr Rosen has served as consultant for Ortho Dermatologics. Dr Vlahovic has served as speaker and investigator for Ortho Dermatologics. Dr Gupta has served as a consultant, speaker, and investigator for Ortho Dermatologics. Dr Pillai is an employee of Bausch Health US, LLC, and may hold stock and/or stock options in its parent company. Dr Guenin is an employee of Ortho Dermatologics and may hold stock and/or stock options in its parent company. Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc. Ortho Dermatologics is a division of Bausch Health US, LLC. |
|
IRB approval status: Reviewed and approved by Schulman IRB (no. 201604687), WCG IRB (no. 00000533), and IntegReview IRB (no. 0000689). |
Vol 84 - N° 4
P. 1140-1142 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?